Diligence memo · auto-generated · as of July 2, 2026
Switch Therapeutics Inc.
Switch Therapeutics Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Switch Therapeutics Inc. operates in Pharma, based in SOUTH SAN FRANCISCO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Switch Therapeutics Inc. has raised $23M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $23M on 2022-09-27.
Most recent recorded round closed around 2022-09-27.
Valuation (modeled)modeled
Provath models Switch Therapeutics Inc. at approximately $327M (range $49M–$819M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.54× the median modeled value of Series B Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 3.8 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 78% of Pharma peers (310 compared).
Modeled value ranks above 82% of those peers.
Closest niche peers: March Therapeutics, Inc., Affect Therapeutics, Inc., SPR Therapeutics, Inc., Multiply Labs, Inc., Notch Therapeutics, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.